These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 11073272)
1. Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives--calcimimetics. Schömig M; Ritz E Nephrol Dial Transplant; 2000; 15 Suppl 5():30-1. PubMed ID: 11073272 [No Abstract] [Full Text] [Related]
2. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites. Schömig M; Ritz E Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270 [TBL] [Abstract][Full Text] [Related]
3. Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy. Schömig M; Ritz E Nephrol Dial Transplant; 2000; 15 Suppl 5():25-9. PubMed ID: 11073271 [No Abstract] [Full Text] [Related]
4. Prevention of uremic bone disease using calcimimetic compounds. Olgaard K; Lewin E Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775 [TBL] [Abstract][Full Text] [Related]
5. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. Chin JI; Miller SC; Wada M; Nagano N; Nemeth EF; Fox J J Am Soc Nephrol; 2000 May; 11(5):903-911. PubMed ID: 10770968 [TBL] [Abstract][Full Text] [Related]
6. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163 [TBL] [Abstract][Full Text] [Related]
7. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro. Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847 [TBL] [Abstract][Full Text] [Related]
8. [Calcimimetics--a new treatment for hyperparathyroidism?]. Piecha G; Chudek J; Wiecek A Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961 [TBL] [Abstract][Full Text] [Related]
12. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. Fox J; Lowe SH; Petty BA; Nemeth EF J Pharmacol Exp Ther; 1999 Aug; 290(2):473-9. PubMed ID: 10411552 [TBL] [Abstract][Full Text] [Related]
13. The pharmacology of bone. Raisz LG Ration Drug Ther; 1971 Jun; 5(6):1-7. PubMed ID: 5565260 [No Abstract] [Full Text] [Related]
15. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Drüeke TB Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252 [TBL] [Abstract][Full Text] [Related]
20. The long-term effect of a calcium diet on the bone tissue, C-cells and parathyroid glands of the rat. Logonder-Mlinsek M; Pajer Z J Endocrinol Invest; 1993 Oct; 16(9):687-90. PubMed ID: 8282964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]